Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crenezumab in Preclinical PSEN1 E280A Mutation Carriers (API ADAD Colombia Trial)
NCT01998841Phase 2Completed
- Sponsor
- Genentech
- Start
- Dec 2013
- Primary completion
- Mar 2022
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of crenezumab in early-onset familial Alzheimer’s disease (FAD), sponsored by Genentech. Started Dec 2013; status: completed.
02
Drugs
crenezumab
03
Conditions
early-onset familial Alzheimer’s disease (FAD)
Beyond the preview
Go deeper on NCT01998841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01998841.